Lilly looking to test Zepbound as health maintenance drug: report
Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Drugmaker Lilly slates another $4.5B for manufacturing and drug development improvements
Eli Lilly is pouring another $4.5 billion into expanding drug manufacturing and development. The diabetes treatment maker ...
FiercePharma2d
High-flying Eli Lilly pushes more chips forward with $4.5B 'Medicine Foundry' project
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...
Eli Lilly plans $4.5 billion facility in LEAP District, bringing investment to $13 billion
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...